Compare Tango Therapeutics Inc. (TNGX) vs Williams Companies Inc (WMB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Tango Therapeutics Inc. vs Williams Companies Inc — how do they compare? Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B), while Williams Companies Inc trades at $72.47 (market cap $91.21B). The key difference: Williams Companies Inc is far larger — about 24.3× Tango Therapeutics Inc.'s market cap, and Williams Companies Inc pays a 2.82% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Tango Therapeutics Inc. for 0 Days and Williams Companies Inc for 58 Days on average.
| TNGX | WMB | |
|---|---|---|
Market Cap | $3.75B | $91.21B |
Volume | 9,619,106 | 6,950,661 |
Sector | Health | Energy |
52-Week High | $32.90 | $79.40 |
52-Week Low | $7.50 | $56.51 |
Typical Hold Time | 0 Days | 58 Days |
Enterprise Value | $2.77B | $121.84B |
Dividend Yield | — | 2.82% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Williams Companies (WMB) trades at $72.80, down 1.85% on the day, with strong technical momentum indicated by bullish moving averages. The company maintains robust profitability with 25.18% net income margin and 24.02% ROE, supported by $5.9B operating cash flow in 2025. Recent earnings show mixed results with Q1 2026 beating expectations while Q4 2025 and Q2 2026 missed. The stock benefits from positive analyst sentiment with 79% buy ratings and $87.08 consensus price target, representing 20% upside potential.
WMB presents a compelling investment case with strong dividend growth, exposure to rising natural gas demand from AI data centers, and resilient midstream business model. Key risks include energy market volatility, high debt levels at $24.74B long-term debt, and execution challenges in capital-intensive projects. The stock's valuation at 29.71 P/E appears reasonable given growth prospects, but investors should monitor debt management and energy price sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →About Williams Companies Inc
Williams is a midstream energy company that owns and operates the large Transco and Northwest pipeline systems and associated natural gas gathering, processing, and storage assets. In August 2018, the firm acquired the remaining 26% ownership of its limited partner, Williams Partners.
Read more on WMB →
